Whilst targeted therapies directed against activating BRAF mutations (found in ∼40% of cutaneous melanomas) have played a role [6–10], it is modern immunotherapies which have delivered the bulk of long-term survival gains [11–13]. The gene discussed is BRAF; the disease is cutaneous melanoma.